What is the market price of acalabrutinib in 2025? Is there a tendency for price fluctuations or corrections?

Acalabrutinib is a new generation Bruton's tyrosine kinase (BTK) inhibitor, mainly used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and other B cell-related malignancies. As an improved version of ibrutinib, acotinib has higher selectivity, stronger inhibitory effect on BTK targets, and relatively low side effects, making it a new choice for many patients. At present, the drug has been launched in China and has been successfully included in medical insurance, providing patients with more financial support.

In the domestic market, the original drug of acotinib is relatively expensive, with the price of each box being as high as more than 20,000 yuan. However, since it has been included in medical insurance, patients who meet the medical insurance reimbursement conditions can enjoy a certain percentage of cost reductions. The specific reimbursement ratio and conditions vary depending on regional policies. Generally, patients covered by medical insurance need to meet specific indications and have a prescription issued at a designated hospital to enjoy the medical insurance price. It is recommended that patients consult their local hospital or medical insurance department to obtain the latest reimbursement information before purchasing drugs.
Compared with the high prices of domestic original drugs, the prices of generic drugs in foreign markets are more affordable, especially the Lao version of generic drugs, which costs about more than 3,000 yuan, which is much cheaper than domestic original drugs. In addition, although the ingredients of the Lao version of generic drugs are basically the same as those of the original drugs, due to differences in production standards, approval processes and regulatory systems, patients need to be cautious when choosing generic drugs, and it is best to make decisions under the guidance of a doctor.
Judging from market trends, the price of acotinib may fluctuate in the future. On the one hand, with the competition of more BTK inhibitors, prices may be adjusted; on the other hand, optimization of medical insurance policies may further reduce patients’ actual drug purchase costs. For patients with long-term treatment needs, it is recommended to pay close attention to drug price changes and medical insurance policy updates to choose the most economical and appropriate drug purchase plan.
Reference: https://www.calquence.com/